EQT

ReliaQuest is a cybersecurity company based in Tampa, Florida, founded in 2007. It specializes in providing a cloud-native security platform called GreyMatter, which offers a comprehensive solution for minimizing data loss and business disruptions. The platform enhances visibility across Security Information and Event Management (SIEM), Endpoint Detection and Response (EDR), and multi-cloud environments, facilitating faster detection and response to security threats. By automating processes throughout the security lifecycle, ReliaQuest enables organizations to manage their security investments effectively and make informed decisions regarding their cybersecurity posture. The company's offerings are designed to protect enterprise environments from security breaches while ensuring compliance and enhancing overall security confidence.

Scale Microgrid Solutions, Inc. is a company that designs, builds, operates, and finances on-site power systems for commercial and industrial facilities across North America. Founded in 2016 and based in Ridgewood, New Jersey, the company specializes in multi-resource clean energy microgrids that support both daily operations and power outage scenarios. Its innovative offerings include the rapid response modular microgrid system, which optimizes solar photovoltaic energy, battery storage, and dispatchable generation. By providing fully-financed microgrid solutions, Scale Microgrid Solutions aims to deliver sustainable, reliable power while simplifying the microgrid development process for its customers.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

PageUp People Limited is a provider of a cloud-based talent management platform designed to assist organizations in effectively managing various human resource functions. Founded in 1980 and headquartered in Melbourne, Australia, the company offers a comprehensive suite of services that includes recruitment, onboarding, performance management, learning and development, succession planning, and analytics. Its platform enables clients to streamline their talent management processes, providing tools for hiring, employee training, and career tracking. PageUp serves a diverse range of clients, including major organizations such as AEGIS, AngloAmerican, and National Australia Bank, and has established additional offices in Sydney, Singapore, Hong Kong, New York, and London.

GeBBS Healthcare Solutions is a technology-enabled company that provides revenue cycle management (RCM) solutions to improve financial performance, compliance, and patient satisfaction. Founded in 2005 and headquartered in Culver City, California, GeBBS offers a range of services including Health Information Management (HIM), Revenue Cycle Management (RCM), Patient Access, Risk Adjustment Solutions, strategic outsourcing, and consulting services. The company serves hospitals, physician groups, health plans, and medical billing companies. With over 6,000 employees globally, GeBBS has formed strategic partnerships with various industry associations and organizations.

Acronis, Inc. is a global provider of backup software, disaster recovery, and secure data access solutions, catering to consumers, small to medium-sized businesses, and enterprises. Established in 2000 and headquartered in Woburn, Massachusetts, Acronis offers a comprehensive range of services, including physical, virtual, and cloud server backup solutions, as well as storage management and secure file sharing. The company's innovative Acronis AnyData engine delivers protection across various devices and environments, while its Acronis Cyber Protect solution integrates data protection with cybersecurity to address safety, accessibility, privacy, authenticity, and security challenges. Acronis employs advanced technologies, including AI-driven anti-malware and blockchain-based data authentication, to safeguard data in cloud, hybrid, and on-premises settings. With a workforce of over 2,000 employees and a presence in 45 locations, Acronis serves a diverse clientele across sectors such as public services, healthcare, and publishing, supporting more than 750,000 businesses worldwide.

FlixBus, operated by FlixMobility, is a notable provider of intercity travel, focusing on affordable, convenient, and environmentally-friendly transportation solutions. Since its inception in 2013, the company has established Europe's largest long-distance bus network and introduced green long-distance trains in 2018, alongside a pilot for all-electric buses in Germany and France. The platform offers travelers a sustainable alternative to private transportation, featuring amenities such as free WiFi, flexible online booking, and innovative ticketing systems. FlixBus also expanded its services to the United States in 2018, bringing its unique travel model to a broader audience. By collaborating with regional bus partners and private train companies, FlixMobility combines technological innovation with traditional transportation expertise, positioning itself as a leader in the evolving mobility landscape. As a result, FlixBus has transformed the travel experience for over 100 million people across Europe and the United States while contributing to job creation in the mobility sector.

Keywords Studios is a prominent provider of technological assistance to the video gaming industry, offering a wide range of specialized services that support various aspects of game development. The company operates through three primary service segments: Create, Globalize, and Engage. Its offerings include game localization, testing, art creation, audio production, and more, effectively enhancing the quality and reach of games. Keywords Studios collaborates with numerous game developers and publishers across the globe, with a presence in countries such as Ireland, the United States, the United Kingdom, Canada, Switzerland, Japan, Italy, France, and India. Through its comprehensive solutions, Keywords Studios plays a crucial role in the game development lifecycle.

CluePoints Inc. is a developer of cloud-based risk-based quality management and monitoring software tailored for the pharmaceutical industry and contract research organizations. Established in 2012 and headquartered in King of Prussia, Pennsylvania, with an additional office in Louvain-la-Neuve, Belgium, CluePoints specializes in risk-based monitoring and central statistical monitoring solutions. Over its 15 years of development, the company has refined its software to utilize unique statistical algorithms that assess the quality, accuracy, and integrity of clinical trial data throughout the study lifecycle. The company's solutions are designed to identify and address anomalous data and site errors, thereby enhancing clinical data quality, optimizing on-site monitoring, and reducing regulatory submission risks. CluePoints' offerings align with guidelines from international regulatory bodies, supporting traditional monitoring and enabling a proactive risk-based monitoring strategy.

Perficient is an information technology consulting and software engineering firm that provides software development and digital consultancy services, IT strategy, and implementation support. The company helps clients leverage Internet-based technologies to improve productivity, competitiveness, and efficiency while strengthening relationships with customers, suppliers, and partners and reducing IT costs. Its offerings include big data analytics, technology platform deployments, enterprise content management, portals and collaboration, management consulting, custom applications, business integration, business process management, and customer relationship management. It serves the healthcare, financial services, retail, and electronics industries.

WSO2 Inc. is a developer of an open-source enterprise middleware platform that facilitates digital transformation for organizations worldwide. Founded in 2005 and headquartered in Mountain View, California, with additional offices across various countries, WSO2 provides tools for enterprise architects to build, integrate, manage, secure, and analyze APIs, applications, and microservices across diverse environments, including on-premises and cloud settings. The company's offerings include WSO2 Developer Studio, WSO2 Private PaaS, and WSO2 App Cloud, which support application development and hosting, as well as customer identity and access management solutions. WSO2's API-first approach enables organizations to efficiently harness their APIs, enhancing user experiences while managing over 1 billion identities and executing trillions of transactions annually. The company serves multiple sectors, including healthcare, finance, retail, and technology, positioning itself as a significant player in the digital landscape.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Onera Health, Inc. specializes in sleep diagnostic solutions and services aimed at identifying sleep disorders such as insomnia, sleep apnea, and narcolepsy. Founded in 2017 and headquartered in Palo Alto, California, with a research and development office in Eindhoven, the Netherlands, the company utilizes advanced sleep diagnostic patch systems that collect and analyze sleep data. These innovative solutions are designed to enhance patient care by providing comprehensive sleep test data to healthcare professionals across various settings, thereby improving the management of sleep-related ailments and potentially benefiting other medical fields through remote monitoring of chronic conditions. Onera Health's mission is to improve the health and quality of life for individuals struggling with sleep issues while also contributing to cost reductions in healthcare.

Heritage Environmental Services is a privately held environmental services firm based in Indianapolis, Indiana, with over 45 years of experience in the industry. The company specializes in providing a range of environmental management and consultancy services. Its offerings include waste treatment, landfill disposal, logistics, laboratory testing, industrial maintenance, and regulatory training. Heritage is committed to assisting clients in navigating environmental challenges while ensuring compliance with regulations and promoting sustainable practices.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that develops and manufactures tissue-based medicines for inflammatory diseases. Incorporated in 2020, Evommune focuses on creating novel strategies to treat these disorders by addressing both symptoms and the underlying causes, thereby halting disease progression. The company employs a proprietary tissue-based platform that accelerates the discovery of innovative treatments, enhancing the potential for clinical success. With a commitment to improving the quality of life for patients, Evommune's pipeline includes initiatives aimed at tackling a range of prevalent inflammatory illnesses, positioning the company as a leader in advancing therapies in the fields of immunology and dermatology.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Radius Global Infrastructure, Inc., headquartered in New York, specializes in the ownership and leasing of essential communications properties for wireless carriers and tower companies. Through its subsidiary, AP Wireless, the company manages a portfolio of ground, rooftop, and other critical sites that support the infrastructure necessary for cell site antenna systems. As of mid-2020, Radius held interests in approximately 6,600 leases across about 5,000 communication sites in the United States and 18 additional countries. Recognized as a significant international aggregator of rental streams in the wireless communications sector, Radius Global Infrastructure focuses on acquiring and managing telecom real property interests, which provides its clients with opportunities to expand into adjacent digital infrastructure markets.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

EQT is a global private equity firm founded in 1994 that invests in mid-market companies through buyouts, expansion capital, growth equity, and infrastructure opportunities. It targets opportunities in Europe, North America, and Asia across sectors such as healthcare, life sciences, technology, industrials, consumer services, and real estate, seeking durable cash flows and meaningful intrinsic value. EQT pursues controlling or co-controlling stakes and collaborates with management to drive growth, improve operations, and expand internationally. The firm maintains a broad geographic footprint and an ownership orientation designed to build market-leading companies with sustainable competitive advantages. By combining sector expertise with disciplined capital allocation, EQT aims to create long-term value for its portfolio and stakeholders while adapting to evolving market dynamics.

Founded in 2005, Storytel is a leading provider of audiobook and e-book streaming services, offering unlimited access to consumers across over 20 markets. The company's extensive library includes books in multiple languages, catering to diverse reading preferences.

Developed, tested, and proven in Germany, Vara is a leading AI-powered breast cancer screening company on a mission to find every deadly breast cancer early. Vara’s Artificial Intelligence (AI) technology is embedded within the German Breast Cancer Screening Program and is backed by some of the most respected institutions in breast cancer screening in the world including Cambridge (UK), Memorial Sloan (US), and Karolinska (Sweden). Vara’s clinical evidence has also been published in Lancet Digital Health, demonstrating that Vara-assisted radiologists significantly outperform average radiologists and are able to find cancers that would otherwise have been missed. Vara works with healthcare stakeholders, radiology service providers, and medical doctor networks to improve access to high-quality screening in Germany, Egypt, India and Mexico.

Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.

Ardoq AS, established in 2013 and headquartered in Oslo, Norway, with offices in New York, London, and Copenhagen, specializes in developing solutions to document and visualize complex computer systems. Its flagship product, Ardoq, combines textual documentation with interactive visualizations, offering features such as automatic visualization generation, real-time collaboration, and model-based documentation. Ardoq serves a wide range of professionals, including business users, developers, project managers, and stakeholders, empowering them to understand interdependencies, plan changes, and make data-driven decisions. The platform enables the entire organization to contribute to documentation, fostering a collaborative environment for digital transformation.

HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

EQT is a global private equity firm founded in 1994 that invests in mid-market companies through buyouts, expansion capital, growth equity, and infrastructure opportunities. It targets opportunities in Europe, North America, and Asia across sectors such as healthcare, life sciences, technology, industrials, consumer services, and real estate, seeking durable cash flows and meaningful intrinsic value. EQT pursues controlling or co-controlling stakes and collaborates with management to drive growth, improve operations, and expand internationally. The firm maintains a broad geographic footprint and an ownership orientation designed to build market-leading companies with sustainable competitive advantages. By combining sector expertise with disciplined capital allocation, EQT aims to create long-term value for its portfolio and stakeholders while adapting to evolving market dynamics.

Blume Global Inc. is a technology company that specializes in developing a cloud-based digital platform designed to streamline and enhance global supply chain operations. The platform provides solutions for asset management, logistics, visibility, optimization, and financial settlement, allowing companies to automate logistics decisions, manage trading partnerships, and gain real-time visibility into their supply chains. Blume Global serves a diverse range of industries including retail, consumer packaged goods, hi-tech, healthcare, life sciences, and automotive. With a core aim of reducing inefficiencies, the company seeks to eliminate $1 trillion of waste in global supply chains, making processes more agile, dependable, and sustainable. Founded in 1993 and headquartered in Pleasanton, California, Blume Global also has a regional office in Hong Kong.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that develops and manufactures tissue-based medicines for inflammatory diseases. Incorporated in 2020, Evommune focuses on creating novel strategies to treat these disorders by addressing both symptoms and the underlying causes, thereby halting disease progression. The company employs a proprietary tissue-based platform that accelerates the discovery of innovative treatments, enhancing the potential for clinical success. With a commitment to improving the quality of life for patients, Evommune's pipeline includes initiatives aimed at tackling a range of prevalent inflammatory illnesses, positioning the company as a leader in advancing therapies in the fields of immunology and dermatology.

Founded in 2005, Storytel is a leading provider of audiobook and e-book streaming services, offering unlimited access to consumers across over 20 markets. The company's extensive library includes books in multiple languages, catering to diverse reading preferences.

Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.

Cypress Creek Renewables is a leading American company specializing in the development and operation of solar energy projects. It employs a data-driven approach to identify and acquire underutilized land for the construction of solar farms, typically ranging from 2 to 20 megawatts in capacity. The company is recognized for owning the largest solar farm east of the Mississippi River. Cypress Creek partners with landowners, utility companies, and local vendors to finance and operate its solar and storage assets, ensuring that local communities receive affordable access to clean energy. Through this model, Cypress Creek not only contributes to the renewable energy landscape but also helps to lower energy costs for consumers compared to traditional fossil fuels.

PAREXEL International Corporation is a biopharmaceutical services company that supports the pharmaceutical, biotechnology, and medical device industries globally. Founded in 1983 and headquartered in Waltham, Massachusetts, PAREXEL offers a wide range of services through three main segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics. The CRS segment specializes in managing clinical trials, including study design, patient enrollment, data management, and pharmacovigilance. The PCMS segment provides consulting services in drug development, regulatory affairs, and market access, assisting clients with product launch strategies and reimbursement issues. Additionally, the Perceptive segment offers technology solutions such as medical imaging, data management systems, and patient engagement applications. By delivering comprehensive expertise in clinical research and commercialization, PAREXEL facilitates scientific discoveries and the development of new treatments.

PRO Unlimited Inc. specializes in developing contingent workforce management solutions tailored for Global and Fortune 500 companies. Founded in 1991 and headquartered in Boca Raton, Florida, the company offers a vendor-neutral Managed Services Program that assists clients in effectively managing the procurement, selection, engagement, and tracking of various contingent workers, including independent contractors, consultants, and freelancers. PRO Unlimited also provides a software-as-a-service platform known as Vendor Management System (VMS), which centralizes the management of contingent workforce activities, statement of work engagements, and independent contractor utilization, thereby enhancing quality control, cost management, and compliance. Additionally, its RatePoint application delivers on-demand rate and hiring intelligence for professional contingent positions. The company's solutions address critical challenges such as supplier management, worker classification, lifecycle tracking, and 1099 management. With locations in the United Kingdom, Japan, California, New York, and Hong Kong, PRO Unlimited is well-positioned to meet the evolving needs of the contingent workforce marketplace.

Anticimex is a global specialist in preventive pest control, headquartered in Stockholm, Sweden, with operations in 17 countries across Europe, Asia-Pacific, and the United States. The company employs approximately 4,500 staff and serves over 3 million customers worldwide. Anticimex offers a comprehensive range of services, including extermination, environmental maintenance, and hygiene solutions, aimed at both businesses and consumers. In addition to traditional pest control methods, the company features innovative offerings such as Anticimex SMART, a digital pest control solution, and pest insurance, enabling clients to maintain pest-free environments and protect their production facilities effectively.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

CYE offers a cybersecurity optimization platform that helps businesses evaluate, quantify, and mitigate cyber risks. Utilizing AI-driven technology, CYE continuously assesses external security posture of third parties to manage supply chain attack risks. Serving Fortune 500 and mid-market companies globally, CYE is headquartered in Israel with offices in New York and London.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

EdgeConneX specializes in infrastructure solutions for content delivery networks, service providers, and other digital businesses. It offers Edge Data Centers, Edge PoPs, and wireless small cell network solutions to optimize data delivery by placing facilities closer to end-users.

Cybin is a biopharmaceutical company dedicated to advancing research and development in psychedelic and medicinal mushrooms. It focuses on creating safe and effective therapeutics for mental health issues, with an emphasis on psilocybin-based products. The company is actively launching these products in jurisdictions where they are permitted and is engaged in clinical studies across North America and other regions. Through strategic partnerships with academic and institutional entities, Cybin seeks to develop novel compounds and delivery mechanisms, aiming to provide innovative treatments for various psychiatric and neurological conditions.

RIMES Technologies Corporation specializes in providing cloud-based managed data services and regulatory technology solutions for financial institutions worldwide. The company offers a range of services, including benchmark data, reference data management, environmental, social, and governance (ESG) data solutions, and RegTech offerings such as market surveillance and regulation control. By catering to investment managers, hedge funds, banks, and sovereign funds, RIMES helps clients reduce costs associated with financial data management while enhancing operational efficiency and compliance. Founded in 1996 and headquartered in New York, RIMES operates several locations globally, including in Boston, Toronto, London, and Shanghai, making it a prominent player in the managed data services sector.

Mabtech AB is a biotech company based in Stockholm, Sweden, specializing in the development and manufacture of monoclonal antibodies and diagnostic kits. Founded in 1986, the company offers a range of products for enzyme-linked immuno sorbent assay (ELISA), enzyme-linked immunospot assay (ELISpot), and FluoroSpot methods, facilitating the detection of cytokines and other immunological molecules. Mabtech's product portfolio includes monoclonal antibodies for various applications, as well as specialized kits for ELISA, ELISpot, and FluoroSpot, which allow for the simultaneous detection of multiple analytes. The company serves a diverse clientele, providing tools for research involving human and animal samples across various species. Mabtech sells its products online and has established locations in the United States, Australia, Germany, and France, operating as a subsidiary of Mabtech Group AB.

Aldevron, LLC is a contract science organization based in Fargo, North Dakota, that specializes in the production of biological products, including plasmid DNA, proteins, antibodies, and nucleic acids. Founded in 1998, the company serves academic and research institutions, as well as pharmaceutical and biotechnology companies, by offering a range of services such as plasmid DNA production, protein production, antibody discovery, and mRNA production. Aldevron focuses on custom manufacturing and provides products for various applications, including gene therapy, gene editing, and diagnostics. Its offerings include DNA vaccine plasmids, reporter plasmids, retroviral vectors, and competent cell production, among others. The company also engages in GMP manufacturing and provides storage, distribution, and stability services, as well as gene synthesis and antibody processing. Aldevron operates both in the United States and Europe, facilitating vital discoveries in the life sciences sector.

Acumatica provides cloud-based business management software tailored for small and mid-sized businesses. Its comprehensive suite includes Financial Management, Distribution Management, Project Accounting, Customer Management, and Manufacturing Edition. The company's xRP Platform enables developers to build custom solutions, while its services encompass implementation planning, training, support, consulting, and upgrades. Acumatica serves various industries such as wholesale distribution, manufacturing, retail, and non-profit organizations.

Founded in 1976, Cast & Crew is a leading provider of payroll services for the Motion Picture, Television, and Commercial Industries. With offices in Burbank, New York, Albuquerque, Atlanta, Baton Rouge, Detroit, Toronto, and Vancouver, the company offers production accounting software and financial services tailored to the entertainment industry. Cast & Crew's services include payroll processing, labor relations, residual, worker compensation, production incentive financing, health benefits management, and more. The company prides itself on its knowledgeable and experienced staff who provide 24/7 support and are dedicated to addressing client issues promptly. Cast & Crew has built a reputation for responsiveness and reliability, fostering long-lasting client relationships based on mutual reliance, integrity, and trust. The company's commitment to excellence and industry expertise has made it a trusted partner in the entertainment business.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

Veritas Petroleum Services provides testing, inspection and advisory solutions for the maritime sector, supported by five laboratories worldwide. It delivers fuel quality testing, bunker quantity surveys, oil condition monitoring and transformer oil testing, along with additional testing services and decarbonisation support. Through these offerings, the company helps clients optimize fuel management, reduce fuel costs, improve operational efficiency and ensure compliance with marine fuel regulatory requirements.

Endotronix develops and manufactures implantable wireless pulmonary artery pressure sensors for early detection of worsening heart failure. The company's platform includes a cloud-based disease management data system, enabling remote patient monitoring.

Zemax, LLC is a software development company based in Kirkland, Washington, specializing in optical and illumination design. Founded in 2014, Zemax provides advanced software solutions for a variety of applications, including projection lenses, binocular lenses, collimating lenses, and biomedical imaging. The company's offerings are tailored to industries such as aerospace, defense, medical and life sciences, instrumentation, optics, and lighting. Zemax's software is known for its technical capabilities, user-friendliness, and accuracy, facilitating efficient collaboration between optical and mechanical engineers. In addition to software, Zemax also offers training and support services to enhance the design process for its users.

Azelis is a global distributor of specialty chemicals and food ingredients, offering a broad portfolio and value-added services to business customers. The company combines extensive local knowledge with an international network to support formulation, application development, and technical problem-solving, delivering tailored solutions. It serves multiple regions, including Europe, the Middle East and Africa, the Americas, and Asia-Pacific, and provides digital tools and online portals that help buyers access information on suppliers, products, and services.

Rainier Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to specifically block the activity of fibroblast growth factor receptor 3 (FGFR3). This innovative treatment aims to improve outcomes for patients with both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics, Inc. before rebranding in November 2018. Through its advanced therapeutic technology, Rainier Therapeutics seeks to enhance treatment options for those affected by this challenging disease.

BBS Automation GmbH is a provider of automation solutions and engineering services, specializing in the design, development, manufacturing, and installation of automated assembly and testing systems. The company serves a diverse range of industries, including automotive, aerospace, life sciences, consumer goods, electronic devices, energy storage, and renewable energy. BBS Automation also offers leak detection, build-to-print services, and winding technology solutions, along with training and after-sales support. With nearly 550 employees, the company operates production sites in Germany, China, Malaysia, and the United States, partnering with prominent global clients. Founded in 1891 and headquartered in Garching bei München, Germany, BBS Automation is committed to delivering flexible and high-quality automation solutions for complex manufacturing and testing processes.

Simplify Medical, Inc. is a medical device company specializing in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs intended for spinal use. Founded in 2013 and based in Sunnyvale, California, it offers innovative products such as the Simplify Disc, a non-metallic, MRI-compatible artificial cervical disc that preserves motion while allowing for full diagnostic imaging without the need for traditional CT scans. This technology minimizes patient exposure to ionizing radiation and is tailored for skeletally mature patients undergoing reconstruction at one level from C3 to C7 following discectomy procedures. Simplify Medical markets its products through distributors in the United Kingdom, Germany, and other international markets. The company was previously known as Simplify Delaware, Inc. before rebranding in February 2015.

Founded in 1978, Fenix Marine Services operates one of the largest container terminals in the Port of Los Angeles. It provides comprehensive handling services including stevedoring, intermodal trucking, storage, maintenance, and rail-vessel planning to optimize shipping line productivity.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Lumos Fiber is a telecommunications company offering fiber optic internet, Wi-Fi, digital TV, voice services, and wired/wireless telecommunications solutions for businesses across North Carolina, South Carolina, and Virginia.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Simplify Medical, Inc. is a medical device company specializing in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs intended for spinal use. Founded in 2013 and based in Sunnyvale, California, it offers innovative products such as the Simplify Disc, a non-metallic, MRI-compatible artificial cervical disc that preserves motion while allowing for full diagnostic imaging without the need for traditional CT scans. This technology minimizes patient exposure to ionizing radiation and is tailored for skeletally mature patients undergoing reconstruction at one level from C3 to C7 following discectomy procedures. Simplify Medical markets its products through distributors in the United Kingdom, Germany, and other international markets. The company was previously known as Simplify Delaware, Inc. before rebranding in February 2015.

Certara Inc. is a company specializing in biosimulation software and technology that enhances drug discovery, development, and regulatory processes. Founded in 2008 and headquartered in Princeton, New Jersey, Certara serves over 1,650 biopharmaceutical companies, academic institutions, and regulatory agencies worldwide. Its comprehensive platform integrates modeling and simulation, regulatory science, and market access solutions, enabling clients to streamline clinical trials, expedite regulatory approvals, and improve patient access to medicines. Certara's technology-enabled services encompass mechanistic and empirical biosimulation, drug development strategy, clinical pharmacology, regulatory writing, and market access. The company operates across multiple regions, including North America, Europe, and Asia Pacific, with a significant presence in various countries.

Global Gateway South Terminal operates as a container terminal yard in the North American Port of Los Angeles, California.

Founded in Switzerland in 1990, Open Systems specializes in managed security services for global enterprises. It offers a range of services including network security, application delivery, identity management, global connectivity, and integrated service management, serving sectors such as finance, healthcare, infrastructure, and retail.

Rainier Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to specifically block the activity of fibroblast growth factor receptor 3 (FGFR3). This innovative treatment aims to improve outcomes for patients with both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics, Inc. before rebranding in November 2018. Through its advanced therapeutic technology, Rainier Therapeutics seeks to enhance treatment options for those affected by this challenging disease.

Dorner Manufacturing, established in 1966 and located in Hartland, Wisconsin, specializes in the design and production of custom conveyor systems tailored for various industries, including automation, material handling, metalworking, packaging, and medical sectors. The company addresses the conveyor automation needs of clients by offering industrial, packaging, and sanitary solutions. In addition to manufacturing conveyor systems, Dorner provides essential services such as replacement parts, preventative maintenance programs, installation supervision, and maintenance training. With a reputation for enhancing efficiency and productivity, Dorner serves a diverse clientele from over 1,200 industries globally, contributing to improved operational outcomes and return on investment.

Lumos Networks Corp. is a fiber-based service provider in the Mid-Atlantic region. The Company provides data, broadband, voice and Internet protocol (IP) services over fiber optic network. The Company offers a range of data and voice products supported by approximately 5,800 fiber-route miles in Virginia, West Virginia, and portions of Pennsylvania, Maryland, Ohio and Kentucky. Its products and services include metro Ethernet, IP services, business advantage bundle, managed router service, broadband, voice services and Web hosting. On October 14, 2011, NTELOS Holdings Corp. announced a distribution date of October 31, 2011, for the spin-off of Lumos Networks Corp.

OxThera AB is a biopharmaceutical company focused on developing innovative therapies for the treatment of primary and secondary hyperoxaluria, a condition that can lead to kidney damage. Founded in 2005 and headquartered in Stockholm, Sweden, with an additional facility in Knoxville, Tennessee, OxThera specializes in products that utilize bacteria and enzymes to manage oxalate levels in the body. Its leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced endogenously, and Oxazyme, a non-systemic oral drug made from recombinant oxalate decarboxylase aimed at treating dietary hyperoxaluria and preventing kidney stones. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in addressing unmet medical needs in this therapeutic area. The company holds worldwide patents for its unique compositions and treatment methods targeting hyperoxaluria.

XP Solutions Inc., founded in 1974 and based in Portland, Oregon, is a leading provider of sustainable drainage and flood hazard software for the civil engineering and environmental sectors. The company offers a range of software solutions, including MicroDrainage for sustainable drainage systems, xpdrainage for stormwater controls, xprafts for hydrologic and hydraulic analysis, xpswmm for stormwater and flood modeling, xpstorm for stormwater and flood management, xp2d for 2D overland flow modeling, and xpsite3d for site design with integrated drainage. These tools are used globally by government agencies, engineering companies, and environmental organizations to plan, design, simulate, and manage the impact of human interaction with the natural world. XP Solutions operates as a subsidiary of Cardno Limited and sells its products through a network of distributors worldwide.

Rotation Medical Inc. is a medical technology company based in Plymouth, Minnesota, that specializes in the development of a minimally invasive rotator cuff implant system aimed at treating rotator cuff disease. The company's innovative implant system utilizes a collagen scaffold designed to be affixed to the affected rotator cuff tendon, offering a surgical solution for managing and protecting tendon injuries. This system is particularly beneficial for patients with small rotator cuff tears and provides additional protection for those with larger tears. Founded in 2009, Rotation Medical was originally known as Denali Medical Inc. before rebranding in March 2010. As of December 2017, the company operates as a subsidiary of Smith & Nephew plc.

Direct ChassisLink, Inc. (DCLI) is a leading provider of marine chassis leasing and container management services, primarily serving the United States intermodal industry. Originally established in 1988 as Maersk Container Service Company, the organization evolved through several name changes and a focus shift towards chassis maintenance and leasing. By 2009, DCLI emerged as a distinct brand after Maersk divested its chassis interests, allowing the company to concentrate on offering chassis on a fee-per-day basis to motor carriers. DCLI specializes in both marine and domestic container chassis, facilitating efficient over-the-road transportation of containerized freight to and from ports, railyards, and customer locations. The company's services are tailored to meet the needs of logistics and operations professionals, enhancing the overall efficiency of intermodal transportation.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Rainier Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to specifically block the activity of fibroblast growth factor receptor 3 (FGFR3). This innovative treatment aims to improve outcomes for patients with both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics, Inc. before rebranding in November 2018. Through its advanced therapeutic technology, Rainier Therapeutics seeks to enhance treatment options for those affected by this challenging disease.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

FocusVision is a company focused on delivering deep customer insights that extend beyond mere feedback to uncover the motivations and emotions that drive consumer behavior. Founded in 1990 and headquartered in New York, the firm offers a comprehensive suite of experience insights software solutions, including advanced surveys, online interviews, focus groups, and qualitative research community tools. These solutions enable businesses to map customer journeys, test brand health, assess product concepts, and gather employee feedback. FocusVision serves a diverse range of clients, including major corporations such as Facebook, Procter & Gamble, and Microsoft, and is recognized for its innovative approach to customer experience management, having received the 2018 Martech Breakthrough Award. With additional offices in several U.S. cities and Europe, FocusVision aims to empower brands to authentically connect with their customers by revealing the underlying truths that shape their perceptions and actions.

Kuros Biosciences is a Swiss biopharmaceutical company founded in 2000 as a spin‑off of ETH Zürich. It develops tissue‑repair and bone‑regeneration products built on proprietary technology platforms derived from research at ETH Zürich, the University of Zürich and CalTech. The company acquired Xpand Biotechnology in 2017 to expand its MagnetOs family of bone graft substitutes, which are approved in the EU for orthopedic, spinal and dental applications and in the United States for posterolateral spinal fusion. A putty formulation is pending regulatory submission. Neuroseal, a novel dural‑sealing biomaterial, is under CE review. Kuros also pursues a pipeline of clinical‑stage products, including KUR‑111 and KUR‑113 for fracture repair and a fibrin‑PTH combination that promotes bone formation. The company collaborates with Checkmate Pharmaceuticals on the oncology candidate CYT003 and maintains a legacy portfolio of medical‑device and pharmaceutical assets.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Ryckman Creek Resources, LLC, a subsidiary of Peregrine Midstream Partners, has received approval from the Federal Energy Regulatory Commission (FERC) to develop a new interstate natural gas storage field 25 miles southwest of the Opal Hub in Uinta County, Wyoming. It will be the largest independently-owned natural gas storage project serving the Opal Hub area. Development of the Ryckman Creek Gas Storage Project will consist of converting an existing partially-depleted oil and gas field into an HDMC gas storage facility with first-phase working gas capacity of approximately 35 Bcf. Phase I maximum injection capability will exceed 350,000 Mcfd with maximum withdrawals of approximately 480,000 Mcfd.

Rotation Medical Inc. is a medical technology company based in Plymouth, Minnesota, that specializes in the development of a minimally invasive rotator cuff implant system aimed at treating rotator cuff disease. The company's innovative implant system utilizes a collagen scaffold designed to be affixed to the affected rotator cuff tendon, offering a surgical solution for managing and protecting tendon injuries. This system is particularly beneficial for patients with small rotator cuff tears and provides additional protection for those with larger tears. Founded in 2009, Rotation Medical was originally known as Denali Medical Inc. before rebranding in March 2010. As of December 2017, the company operates as a subsidiary of Smith & Nephew plc.

Heart Metabolics Limited is a pharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens, making it harder for blood to leave the heart and often leading to heart failure or sudden death. With over 100,000 cases in the United States alone, HCM can be particularly severe in young adults and athletes. Current cardiovascular drugs do not help all patients, highlighting a significant medical need. Heart Metabolics is addressing this by developing perhexiline, an approved drug in Australia and New Zealand for angina, as a therapeutic for all types of HCM. The company plans to conduct clinical trials in the U.S. and seek FDA approval for perhexiline as an orphan drug, which it has already designated.

Synagro Technologies, Inc. is a provider of waste capture and conversion services for municipal and industrial water and wastewater facilities across the United States. Founded in 1986 and headquartered in Houston, Texas, the company specializes in recycling industrial and municipal waste, as well as organic by-products, into environmentally sustainable resources. Its comprehensive range of services includes lagoon cleaning, dewatering, dredging, and thermal reduction, among others. Additionally, Synagro offers renewable energy generation and produces recycled biosolids fertilizer, compost, and other byproducts. The company caters to a diverse clientele, including municipal entities and various industries such as renewable energy, chemical manufacturing, food and beverage processing, pharmaceuticals, and oil and gas. Synagro Technologies, Inc. was previously known as BMP Marketing, Inc. and underwent a name change in 1994. The company also filed for reorganization under Chapter 11 in 2013.

Cobalt Technologies is a biotechnology company founded in 2005 and headquartered in Mountain View, California. The company specializes in developing innovative technologies for the production of biofuels, particularly focusing on next-generation bio n-butanol. Cobalt's advancements enable the creation of low-cost, commercial-scale biobutanol, which serves as a sustainable alternative to petroleum-based products. This bio-based chemical can be utilized in a wide range of applications, including fuels, jet fuel, bio-based plastics, synthetic rubber, paints, adhesives, and solvents. By providing cost-effective substitutes to traditional petroleum-derived chemicals, Cobalt Technologies aims to contribute to cleaner burning fuels and a reduced environmental impact.

Celladon Corporation, established in 2000 and headquartered in La Jolla, California, is a biotechnology company focused on developing molecular therapies for treating heart failure. The company's primary product candidate is MYDICAR, an enzyme replacement therapy aimed at addressing the key enzyme deficiency in advanced heart failure. This therapy targets SERCA2a, an enzyme crucial for regulating calcium cycling and contractility in heart muscle cells.

Anticimex is a global specialist in preventive pest control, headquartered in Stockholm, Sweden, with operations in 17 countries across Europe, Asia-Pacific, and the United States. The company employs approximately 4,500 staff and serves over 3 million customers worldwide. Anticimex offers a comprehensive range of services, including extermination, environmental maintenance, and hygiene solutions, aimed at both businesses and consumers. In addition to traditional pest control methods, the company features innovative offerings such as Anticimex SMART, a digital pest control solution, and pest insurance, enabling clients to maintain pest-free environments and protect their production facilities effectively.

Cobalt Technologies is a biotechnology company founded in 2005 and headquartered in Mountain View, California. The company specializes in developing innovative technologies for the production of biofuels, particularly focusing on next-generation bio n-butanol. Cobalt's advancements enable the creation of low-cost, commercial-scale biobutanol, which serves as a sustainable alternative to petroleum-based products. This bio-based chemical can be utilized in a wide range of applications, including fuels, jet fuel, bio-based plastics, synthetic rubber, paints, adhesives, and solvents. By providing cost-effective substitutes to traditional petroleum-derived chemicals, Cobalt Technologies aims to contribute to cleaner burning fuels and a reduced environmental impact.

Argenx is a biopharmaceutical company based in the Netherlands, dedicated to developing antibody-based therapies for rare autoimmune diseases.

Peregrine Midstream Partners is a privately-held company based in Houston, Texas, founded in 2009 by the former founders and management team of Falcon Gas Storage. The company specializes in the midstream energy sector, focusing on natural gas storage, transportation, processing, and NGL extraction. Additionally, Peregrine is involved in crude oil and NGL production, storage, handling, marketing, and sales, particularly in conjunction with HDMC natural gas storage development and operations. The firm also offers midstream asset management and advisory services, along with energy commodity risk management, positioning itself as a key player in the energy market.

Atos Medical, founded in 1986, specializes in manufacturing therapeutic devices aimed at enhancing the quality of life for laryngectomized patients. The company produces a range of products, including voice prosthetics, pulmonary rehabilitation devices, adhesives, laryngectomy tubes, and hands-free speaking devices. With its headquarters in Sweden, Atos Medical operates a state-of-the-art clean room and laboratory to support research and development. The company has established a significant international presence, with subsidiaries in multiple countries, including the USA, UK, Germany, Spain, the Netherlands, Belgium, Sweden, and Switzerland, along with exclusive distributors in around 60 countries.

Cobalt Technologies is a biotechnology company founded in 2005 and headquartered in Mountain View, California. The company specializes in developing innovative technologies for the production of biofuels, particularly focusing on next-generation bio n-butanol. Cobalt's advancements enable the creation of low-cost, commercial-scale biobutanol, which serves as a sustainable alternative to petroleum-based products. This bio-based chemical can be utilized in a wide range of applications, including fuels, jet fuel, bio-based plastics, synthetic rubber, paints, adhesives, and solvents. By providing cost-effective substitutes to traditional petroleum-derived chemicals, Cobalt Technologies aims to contribute to cleaner burning fuels and a reduced environmental impact.

Restaurant Technologies, Inc. specializes in edible oil management and distribution systems in the United States. The company provides a comprehensive oil management solution that includes hardware, software, installation, training, and ongoing support, addressing the entire process from oil delivery and storage to handling and disposal. Its offerings include the Total Oil Management software, which is a web-based portal that gives foodservice operators visibility into performance and compliance, as well as portable oil systems and subscription-based filtration monitoring solutions. Additionally, the AutoMist system automates the cleaning of kitchen hoods and flues, thereby improving safety and efficiency. Serving over 30,000 clients, including quick-service and full-service restaurants, grocery delis, hotels, and universities, Restaurant Technologies operates 41 depots across the nation and employs over 1,000 staff members. The company, headquartered in Mendota Heights, Minnesota, was established in 1996 and has built a reputation for enhancing kitchen safety and sustainability in the foodservice industry.

Activaero develops controlled breathing technologies for efficient pulmonary delivery of inhaled therapeutics. Its flagship product, AKITA, uses smart card technology to enable safe and precise local drug deposition in the lungs, targeting conditions such as asthma, COPD, cystic fibrosis, and idiopathic pulmonary fibrosis.

Argenx is a biopharmaceutical company based in the Netherlands, dedicated to developing antibody-based therapies for rare autoimmune diseases.

Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.

BMEYE B.V. is a Dutch company specializing in non-invasive cardiovascular monitoring technologies. Founded in 2005 and based in Amsterdam, BMEYE focuses on the research and development of innovative medical devices for measuring blood pressure and cardiac output. Its product portfolio includes several advanced monitoring systems such as Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version for continuous measurements; and Finometer, a stationary monitor that provides non-invasive brachial pressure and beat-to-beat hemodynamic assessments. Additionally, the company offers Nexfin and ccNexfin monitors, which are designed for cardiology and critical care applications respectively, along with various specialized devices like BeatScope for arterial waveform analysis, Modelflow for aortic flow calculations, and Cardiopres for studying the interplay of electrophysiology and hemodynamics. BMEYE distributes its products through a network of distributors across the Netherlands and international markets.

Pasteuria Bioscience is a biotechnology company focused on developing biological nematicides to control nematode pests in crops and turf. It leverages a proprietary fermentation-based manufacturing method to produce multiple Pasteuria strains, enabling farmers to suppress nematodes without harming non-target organisms. Originating from University of Florida research and spun out from Entomos, the company has advanced its technology toward commercial-scale production and regulatory acceptance, supported by venture funding and ongoing field trials. Its portfolio emphasizes product development and an expanding intellectual property position to offer environmentally friendly alternatives to chemical nematicides.

Midland Cogeneration Venture (MCV) operates a natural gas-fired combined electrical energy and steam generation plant in the United States. It serves as a significant supplier of electrical energy across Michigan and the midcontinent region, catering to various customers, including chemical production companies and sugar refining mills. By employing combined-cycle heat and power (CHP) technology, MCV efficiently converts natural gas into electricity and process steam, contributing to a cleaner energy economy. The company focuses on delivering reliable and cost-competitive energy solutions to its diverse clientele, including households and industrial users.

BMEYE B.V. is a Dutch company specializing in non-invasive cardiovascular monitoring technologies. Founded in 2005 and based in Amsterdam, BMEYE focuses on the research and development of innovative medical devices for measuring blood pressure and cardiac output. Its product portfolio includes several advanced monitoring systems such as Finapres, a continuous finger blood pressure monitor; Portapres, an ambulatory version for continuous measurements; and Finometer, a stationary monitor that provides non-invasive brachial pressure and beat-to-beat hemodynamic assessments. Additionally, the company offers Nexfin and ccNexfin monitors, which are designed for cardiology and critical care applications respectively, along with various specialized devices like BeatScope for arterial waveform analysis, Modelflow for aortic flow calculations, and Cardiopres for studying the interplay of electrophysiology and hemodynamics. BMEYE distributes its products through a network of distributors across the Netherlands and international markets.

Cobalt Technologies is a biotechnology company founded in 2005 and headquartered in Mountain View, California. The company specializes in developing innovative technologies for the production of biofuels, particularly focusing on next-generation bio n-butanol. Cobalt's advancements enable the creation of low-cost, commercial-scale biobutanol, which serves as a sustainable alternative to petroleum-based products. This bio-based chemical can be utilized in a wide range of applications, including fuels, jet fuel, bio-based plastics, synthetic rubber, paints, adhesives, and solvents. By providing cost-effective substitutes to traditional petroleum-derived chemicals, Cobalt Technologies aims to contribute to cleaner burning fuels and a reduced environmental impact.

TitanX Holding specializes in providing engine cooling solutions for manufacturers of trucks, buses, off-highway equipment, and industrial diesel engines. The company manufactures a range of thermal management products, including engine, oil, bus, and genset cooling systems. With facilities located in Sweden, the United States, and Brazil, TitanX also offers design and testing services for its products, aimed at supporting clients in their pursuit of cleaner transportation solutions.

Asoyia, LLC is a company based in Iowa City, Iowa, specializing in the production of soybeans and soybean oil. Established in 2004, Asoyia serves a diverse clientele that includes food processors, institutional food management services, and restaurant chains. The company distributes its products through various distributors, ensuring a wide reach in the market. In addition to its headquarters in Iowa City, Asoyia operates locations in Des Moines and Cedar Rapids, Iowa, as well as Bloomington, Illinois.

Hyperion Therapeutics, Inc. is a biopharmaceutical company based in Brisbane, California, focused on developing and commercializing therapies for orphan diseases. The company specializes in treatments for urea cycle disorders (UCD), offering products such as RAVICTI, a nitrogen-binding agent used for the chronic management of UCD in both adults and pediatric patients. In addition to RAVICTI, Hyperion provides BUPHENYL and AMMONAPS for the treatment of specific UCD subtypes. The company is also exploring the application of glycerol phenylbutyrate, the active ingredient in RAVICTI, for the treatment of hepatic encephalopathy. Founded in 2006, Hyperion Therapeutics aims to address the needs of underserved patient populations through its innovative therapeutic developments.